Cancer: a chronic disease paced by innovation?

http://www.medpagetoday.com/HematologyOncology/ProstateCancer/46090

http://am.asco.org/adding-chemotherapy-hormone-therapy-men-newly-metastatic-prostate-cancer-leads-%E2%80%98unprecedented

http://meetinglibrary.asco.org/content/127755-144

Actual advances in prostate cancer:

Intent to treat analysis	ADT	ADT + D	P value	Hazard ratio (95%CI*)
PSA < 0.2 at 12 mos	9.4%	19.7%	<0 .0001="" td="">
Median OS (mos)
N=790	42.3	52.7	0.0006	0.63 (0.48, 0.82)
N=520-HV	32.2	49.2	0.0012	0.62 (0.46, 0.83)
N=270-LV	NR**	NR	0.0836	0.58 (0.31, 1.08)
* CI: confidence intervals; **NR: not reached.

D = Docetaxel